Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on April 30, 2014, to report unaudited financial results for the quarter ended March 31, 2014. The company operates in the genomics sector, focusing on the installation of PacBio RS II systems and consumables.
Key Financial Metrics
- Revenue: $11.6 million for Q1 2014.
- Gross Profit: $2.7 million.
- Gross Margin: 23.0%.
- Operating Expenses: $20.9 million (including $2.1 million in non-cash stock-based compensation).
- Cash and Investments: $118.7 million as of March 31, 2014.
- Backlog: 13 instruments as of March 31, 2014.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased from $5.6 million in Q1 2013 to $11.6 million in Q1 2014. This growth was driven by the installation of nine PacBio RS II systems (compared to three in Q1 2013) and $1.7 million in revenue from a development agreement with Roche Diagnostics.
- Margin Expansion: Gross margin improved from 16.7% in Q1 2013 to 23.0% in Q1 2014, primarily due to increased contractual revenue.
- Operating Expenses: Expenses decreased slightly from $21.5 million in Q1 2013 to $20.9 million in Q1 2014.
- Liquidity: Cash and investments increased by $6.2 million from the prior quarter end (December 31, 2013), largely due to $20.6 million raised through an "at-the-market" stock offering.
Guidance, Outlook, and Risks
- Revenue Outlook: Management expects 2014 revenue to exceed 2013 levels, though quarterly fluctuations are anticipated.
- Margin Outlook: Gross margins for the remainder of 2014 are expected to remain near current levels, subject to product mix and geography.
- Expense Outlook: Quarterly operating expenses are anticipated to remain consistent with Q1 2014 levels for the rest of the year.
- Risks: The filing contains forward-looking statements subject to risks and uncertainties described in the company's 10-Q and 10-K filings. Actual results may differ materially from projections.
Investor Verification Checklist
- Verify the sustainability of the $1.7 million revenue contribution from the Roche Diagnostics development agreement.
- Confirm the conversion rate of the 13-instrument backlog into recognized revenue in subsequent quarters.
- Monitor the burn rate of cash given operating expenses of $20.9 million against revenue of $11.6 million.
- Review the terms and remaining capacity of the "at-the-market" offering program used to raise $20.6 million.